Yunhe Tang

Yunhe Tang

Auto-generated profile, based on publicly available information

Yunhe Tang

Department of Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Annals of Hepatology
Verified
Journal Article
Open access
LKLorenz Kocheise
Lorenz Kocheise
JKJan Kempski
Jan Kempski
YTYunhe Tang
Yunhe Tang
LBLorenz Balcar
Lorenz Balcar
VBVictoria Berger
Victoria Berger
KSKornelius Schulze
Kornelius Schulze
Immunotherapy with atezolizumab/bevacizumab (atezo/bev) is an established first-line treatment for patients with non-resectable hepatocellular carcinoma (HCC). Despite notable successes, only a subset of patients shows treatment response, highlighting the need for biomarkers to identify those likely to benefit from this therapy. In this biomarker study, 143 patients with atezo/bev-treated HCC were enrolled across three European centers. Baseline cytokine levels were measured using a flow cytometric multiplex bead assay. Overall survival (OS) analysis, reported as hazard ratios (HR), was conducted in an unbiased manner, with patients divided into a discovery cohort (one center, 63 patients) and a validation cohort (two centers, 80 patients). Our cohorts show typical baseline characteristics of Western HCC patients, with alcohol-related liver disease (35.0 %) and hepatitis C (21.7 %) as the main HCC etiologies. Elevated serum IL-6 (cut-off 18.22 pg/ml) was associated with poor OS in both the discovery (HR 2.6, 95 % CI 1.2-5.6, p = 0.013) and validation cohorts (HR 2.4, 95 % CI 1.3-4.4, p = 0.005). Multivariate analysis confirmed elevated IL-6 to be a significant prognostic biomarker of poor OS (HR 2.1, 95 % CI 1.1-3.9, p = 0.021) after adjusting for established risk factors. We identify elevated serum IL-6 levels as prognostic biomarker in patients with advanced HCC in Western countries. Importantly, this association was independent of infection with viral hepatitis, thus extending the previously reported associations between IL-6 and treatment response in East Asian cohorts.